The usual methods for prenatal diagnosis of /3-thaiassemia and other hemoglobinopathies by assay of fetal blood erythrocytes are either complex (analysis of globin chains synthesis by carboxymethylcellulose chromatography) or only semiquantitative [ by assaying fetal blood samples obtained by cordocentesis between the 18th and 22nd weeks of pregnancy is still important when DNA testing during the first trimester is not feasible. The methods usually used in our laboratory for this purpose are isoelectric focusing (IEF) of hemoglobin (Hb) (1, 2) and carboxymethylcellulose (CMC) chromatography (3, 4)5 The latter method, although considered the method of choice for this kind of investigation, is quite complex and requires the use of radioactive isotopes. ZEF, in our experience, is simple and rapid and is conclusive in -80% of the diagnoses.
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Its main limitations are the need for fetal blood samples uncontaminated with maternal blood and also some preliminary sample preparation steps. Moreover, IEF is only semiquantitative, the result being based on the intensity ofthe Hb A band.
The introduction of a new simple HPLC method allowing precise quantification of the various Hb fractions (5) prompted us to evaluate its reliability in prenatal diagnosis ofhemoglobinopathies. This method, which utilizes a commercial column designed for Hb A2 measurement, allows much more rapid and precise evaluation of fetal blood samples in the midtrimester of pregnancy than do the above methods. Here, we demonstrate that measurement of the Hb A fraction in fetal blood samples completely discriminates between affected and unaffected fetuses. The only requirement is the availability of uncontaminated fetal blood.
MaterIals and Methods
Between January 1988 and January 1990 we examined 229 fetal blood samples obtained by cordocentesis (gestation weeks 18-22), 212 of which were uncontaminated with maternal blood. These samples were from couples at risk for /3-thalassemia (n = 193), /3-thalassemial#{244}f3-thalassemia (n = 6), and /3-thalassemia! abnormal hemoglobins (Hb S, Hb C, Hb Lepore, Hb J Sardinia) (n = 13). All samples were evaluated for possible contamination by maternal erythrocytes by using the volume distribution curve for erythrocytes (Coulter Channelyzer; Coulter Corp., Hialeah, FL) and the test of Klethauer et al. (6) . Fetal blood samples containing even a small percentage of maternal erythrocytes were examined by CMC chromatography only. In the presence of a macroscopically evident amniotic fluid contamination, samples were washed twice in saline before being processed by HPLC, thereby avoiding any adverse effectsdue to such contamination.
Hb A was measured with a DIAMAT-TM HPLC analyzer (Bio-Rad Labs, Richmond, CA), with the instrument settings modified as described before (5). The hemoglobins were eluted at the following retention times: Hb Aia and Jib Aib at 1.7 miii, A1 at 2.5 miii, F at 3.6 mm, A at 8.5 mm, A2 at 11.7 miii, and S at 13.5 miii. Each run took --15 mm. The reproducibility (CV) of the Hb A quantification, evaluated by assessingthe differences between duplicates, was 3.2% for a mean Hb A content of 2.5%.
We also studied the fetal blood samples by IEF (2) and in a few cases also by CMC chromatography (4). The typical imprecision (CV) of the CMC method is 18.3% (mean fly mass fraction 0.043). Fetal blood samples from unaffected subjects or from subjects homozygous for /3-thalassemia were used as controls.
In agreement with fetal diagnosis, none of the 115 newborns that we checked at birth was affected by /3-thalassemia.
Results
Of the 212 cases considered, 44 were affected by (3-thalassemia major or related hemoglobunopathies and 168 were not affected, as determined with the comparisonmethods used in our laboratory (191 caseswith IEF, 21 with both IEF and CMC chromatography).
The distribution histogram of the relative Jib A concentrations is shown in Figure 1 . A clear cutoff between the 44 affected fetuses (Jib A values 1.8%) and the 168 unaffected fetuses is evident. No false-negative or falsepositive results for /3-thalassemia major or related hemoglobinopathies were obtained, as determined by comparing the HPLC data with the data obtained by the other methods.
A good correlation (P <0.0001) between the Jib A concentrations and the fly ratio was found (Figure 2 ). In our experience, fly values <0.025 identify patients homozygous for /3-thalassemia.
Thirteen fetuses were at risk for /3-thalassemia and (or) abnormal hemoglobuns (Jib S, Jib Lepore, Jib J Sardinia, and Jib C). A small Jib S peak can be associated with the Jib A peak in a fetus heterozygous for Hb S. Also in these cases, the JEF and CMC results always agreed with each other and with the HPLC results. None of the cases at risk showed inheritance of Jib Lepore, Jib C, and Jib J Sardima from the parents, so that approach for evaluating these hemoglobin variants in HPLC during the midtrimester of pregnancy was impossible.
However, adults heterozygous for these he- The dashed lines representthe regression line ±2 S tography has been an important tool for the prevention of this disease (7) . In 1984, introduction of LEF in prenatal diagnosis of /3-thalassemia offered a valid alternative to CMC chromatography in our center by being a simpler, rapid, inexpensive method for examining uncontaminated fetal blood samples (2). However, IEF is a semiquantitative method, and absolute discrimination is impossible in borderline cases (e.g., faint Jib A band), which need to be confirmed by CMC chromatography. An HPLC method involving radioactive isotopes and globin chain separation has also been proposed as an alternative to CMC chromatography (8) for prenatal diagnosis of /3-thalassemia.
The HPLC technique we used does not use radioactive materials and represents a new application of a commercially available system for Jib A2 measurement. This HPLC method is advantageous in terms of simplicity, speed (15 miii per run), and cost (about the same as that of IEF). With regard to the comparison between Jib A measured by HPLC and CMC chromatography of globin chains, the correlation, although statistically significant, is not total. A possible explanation for this could be the large difference in analytical imprecision of the two techniques.
Our results indicate that the method proposed is very reliable, with no overlap between results for affected and unaffected fetuses and producing no false-positive or false-negative results. The possibility of differentiating /3#{176} from fl homozygotea seems beyond the resolution limits of the technique; in fact, our recent experience with couples undergoing first-trimester fetal diagnosis indicates a high incidence off#{176} carriers (54%), whereas very low amounts of Hb A, probably representing the minimum background of the technique, were usually found in affected fetuses (both /3#{176} and /3 homozygotes) at the midtriinester fetal diagnosis. However, a possible overlap between /3#{176} heterozygotes and /3 homozygotes may be excluded, considering that the incidence of affected fetuses in this series is only slightly below that expected and that thalassemia major was excluded at follow-up in 115 cases.
We conclude that Jib A measurement by the HPLC technique proposed here should be the method of choice for prenatal diagnosis of thalassemia and related disorders in the midtrimester of pregnancy. The much more complex and time-consuming CMC chromatography is needed only for those few cases(7.5% in our experience) in which some degree of contamination of fetal samples by maternal eiythrocytes is present.
